Effect of tirzepatide on blood pressure and lipids: A meta‐analysis of randomized controlled trials
Authors' conclusion
Tirzepatide induced clinically meaningful reductions in the levels of systolic and diastolic blood pressure, total cholesterol, LDL cholesterol and triglycerides, along with increases in the level of HDL cholesterol.
Study context
- Population
- RCTs evaluating effects of tirzepatide on blood pressure or lipid profiles7 RCTs
- Comparison
- Tirzepatide effect on blood pressure and lipids
- Outcome
- Effect of tirzepatide on blood pressure and lipids
Pooled result
As reported in the abstract
Systolic blood pressure change
Median
−4.20 mmHg
95% CI −5.17 to −3.23
Tirzepatide 5 mg
Median
−5.34 mmHg
95% CI −6.31 to −4.37
Tirzepatide 10 mg
Median
−5.77 mmHg
95% CI −6.73 to −4.81
Tirzepatide 15 mg
Further pooled results
Total cholesterol change
| Median (%) (95% CI) | |
|---|---|
| Tirzepatide 5 mgDecrease | −3.76 (−5.20% to −2.31%) |
| Tirzepatide 10 mgDecrease | −4.63 (−6.07% to −3.19%) |
| Tirzepatide 15 mgDecrease | −5.93 (−7.36% to −4.49%) |
HDL-C, LDL-C and TG
- Tirzepatide increased HDL-C and decreased LDL-C and TG levels
Original publication
Effect of tirzepatide on blood pressure and lipids: A meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →